Royal Marsden Hospital, Sutton, Surrey, UK.
Pediatr Blood Cancer. 2011 Dec 1;57(6):1074-6. doi: 10.1002/pbc.22992. Epub 2011 Jul 8.
Hair loss was compared between surgery followed by craniospinal radiotherapy (CSRT) or chemotherapy then CSRT (C-CSRT) for medulloblastoma. The proportion of patients exhibiting hair loss in the cranial field was 70.0% (C-CSRT) versus 30.0% (CSRT) (95% CI: 14.7% to 58.9%; P = 0.002). The C-CSRT group also experienced more virtual/complete hair loss over the posterior fossa boost. Age was a significant contributor to hair loss in the cranial field. Persistent significant hair loss is an under-reported late effect of treatment that could influence quality of survival and should be considered in future trial design.
比较了髓母细胞瘤手术后行颅脊髓放疗(CSRT)或化疗后再行 CSRT(C-CSRT)的脱发情况。头皮脱发患者比例为 70.0%(C-CSRT)比 30.0%(CSRT)(95%CI:14.7%至 58.9%;P=0.002)。C-CSRT 组在后颅窝加量照射中也经历了更多的虚拟/完全脱发。年龄是头皮脱发的一个重要因素。持续性显著脱发是治疗的一种被低估的晚期效应,可能会影响生存质量,在未来的试验设计中应加以考虑。